860
Participants
Start Date
March 15, 2019
Primary Completion Date
September 30, 2027
Study Completion Date
September 30, 2027
Pirtobrutinib
Oral
Venetoclax
Oral
Rituximab
IV
Peter MacCallum Cancer Centre, Melbourne
Flinders Medical Centre, Bedford Park
Linear Clinical Research, Nedlands
Ospedale Regionale Bellinzona e Valli, Bellinzona
Columbia University Medical Center, New York
Memorial Sloan Kettering Cancer Center, New York
Northwell Health, New Hyde Park
Roswell Park Cancer Institute, Buffalo
University of Pennsylvania Hospital, Philadelphia
IRCCS Ospedale San Raffaele, Milan
University of North Carolina at Chapel Hill, Chapel Hill
Durham VA Medical Center, Durham
Duke University Medical Center, Durham
Emory Clinic, Atlanta
Mayo Clinic-Jacksonville, Jacksonville
Florida Cancer Specialists ORLANDO/DDU, Lake Mary
Sylvester Comprehensive Cancer Center, Miami
Florida Cancer Specialists, Sarasota
Sarah Cannon Research Institute SCRI, Nashville
IRCCS - AOU di Bologna, Bologna
Ohio State University Hospital, Columbus
Centre Hospitalier Universitaire de Nantes - L' Hopital l'hôtel-Dieu, Nantes
Cleveland Clinic Foundation, Cleveland
Medical College of Wisconsin, Milwaukee
Northwestern University, Chicago
University of Kansas Medical Center, Kansas City
University of Nebraska Medical Center, Omaha
Mary Crowley Cancer Research Center, Dallas
University of Texas MD Anderson Cancer Center, Houston
Utah Cancer Specialists, Salt Lake City
Mayo Clinic of Scottsdale, Scottsdale
Scripps Coastal Medical Center, San Diego
University of California San Francisco, Medical Center at Paranassus, San Francisco
Swedish Medical Center, Seattle
Seattle Cancer Care Alliance, Seattle
Smilow Cancer Hospital at Yale-New Haven, New Haven
Dana-Farber Cancer Institute, Boston
Mayo Clinic, Rochester
Nagoya Medical Center, Nagoya
Hokkaido University Hospital, Sapporo
Tokai University Hospital- Isehara Campus, Isehara
Kochi Medical School Hospital, Nankoku
Tohoku University Hospital, Sendai
National Cancer Center Hospital, Chuo Ku
National Hospital Organization Kyushu Cancer Center, Fukuoka
Kyoto Furitsu Medical University Hospital, Kyoto
Okayama University Hospital, Okayama
Kindai University Hospital, Osakasayama-Shi
Pratia MCM Krakow, Krakow
Instytut Hermatologii I Transfuzjologii, Warsaw
Samsung Medical Center, Seoul
Seoul National University Hospital, Seoul
Karolinska Institutet, Solna
St James's University Hospital, Leeds
Churchill Hospital, Oxford
Derriford Hospital, Plymouth
Lead Sponsor
Eli Lilly and Company
INDUSTRY
Loxo Oncology, Inc.
INDUSTRY